NEW YORK – Following the announcement of a $60 million exclusive global license earlier this week, Veracyte is now gearing up to engage international markets using NanoString Technology's nCounter Flex platform.
While Seattle-based NanoString retains the rights to commercialize the nCounter for research use applications, Veracyte will transition its current diagnostic and prognostic cancer assays onto the platform in order to reach a global audience.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
